$2.29
In the last 1 year, Novo Nordisk A/s has given 82.7% return, outperforming this stock by 142.8%
3.28%
Downside
Day's Volatility :6.93%
Upside
3.78%
9.61%
Downside
52 Weeks Volatility :72.94%
Upside
70.07%
Period | Annexon Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -30.5% | -1.7% | 0.0% |
6 Months | -40.45% | 1.3% | -0.1% |
1 Year | -60.1% | 5.1% | 5.6% |
3 Years | -88.84% | 24.3% | 17.6% |
Market Capitalization | 154.9M |
Book Value | $3.48 |
Dividend Share | 0.0 |
Dividend Yield | 0.0% |
Earnings Per Share (EPS) | -1.81 |
Wall Street Target Price | 15.6 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -41.79% |
Return On Equity TTM | -81.24% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -149.6M |
Diluted Eps TTM | -1.81 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -2.0 |
EPS Estimate Next Year | -1.87 |
EPS Estimate Current Quarter | -0.54 |
EPS Estimate Next Quarter | -0.56 |
What analysts predicted
Upside of 581.22%
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Annexon Inc | -19.39% | -40.45% | -60.1% | -88.84% | -88.84% |
![]() Moderna, Inc. | -12.64% | -32.32% | -15.78% | 41.01% | 434.62% |
![]() Regeneron Pharmaceuticals, Inc. | 0.2% | 0.68% | 20.34% | 45.14% | 111.19% |
![]() Novo Nordisk A/s | -3.66% | 17.13% | 82.69% | 165.14% | 293.9% |
![]() Seagen, Inc. | 3.05% | 4.69% | 56.63% | 11.31% | 161.89% |
![]() Vertex Pharmaceuticals Incorporated | -0.55% | 11.62% | 19.58% | 30.6% | 81.41% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Annexon Inc | NA | NA | NA | -2.0 | -0.81 | -0.42 | 0.0 | 3.48 |
![]() Moderna, Inc. | 34.67 | 34.67 | 0.0 | -3.66 | 0.07 | 0.01 | 0.0 | 44.49 |
![]() Regeneron Pharmaceuticals, Inc. | 21.73 | 21.73 | 9.01 | 41.82 | 0.19 | 0.1 | 0.0 | 225.94 |
![]() Novo Nordisk A/s | 43.3 | 43.3 | 2.03 | 1.65 | 0.82 | 0.22 | 0.01 | 2.52 |
![]() Seagen, Inc. | NA | NA | 18.53 | -3.52 | -0.26 | -0.13 | 0.0 | 13.96 |
![]() Vertex Pharmaceuticals Incorporated | 26.94 | 26.94 | 0.41 | 14.71 | 0.25 | 0.16 | 0.0 | 60.01 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Annexon Inc | Buy | $154.9M | -88.84% | NA | 0.0% |
![]() Moderna, Inc. | Buy | $37.3B | 434.62% | 34.67 | 11.33% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $90.4B | 111.19% | 21.73 | 33.93% |
![]() Novo Nordisk A/s | Buy | $410.6B | 293.9% | 43.3 | 33.4% |
![]() Seagen, Inc. | Hold | $40.6B | 161.89% | NA | -33.55% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $90.2B | 81.41% | 26.94 | 35.4% |
SATTER MANAGEMENT CO., L.P.
Bain Capital Life Sciences Investors, LLC
Redmile Group, LLC
Logos Global Management LP
BlackRock Inc
Federated Hermes Inc
Annexon Inc’s price-to-earnings ratio stands at None
Read Moreour mission is to develop disease-modifying therapeutics for patients suffering from neurological disorders such as huntington’s disease and alzheimer’s disease by targeting complement-mediated neurodegeneration (cmnd).
Organization | Annexon Inc |
Employees | 77 |
CEO | Mr. Douglas Love J.D., Esq. |
Industry | Health Technology |
Innovator S&p 500 Power-jan
$2.29
-3.38%
Energy Fuels Inc/canada
$2.29
-3.38%
Cohen & Steers Closed-end Op
$2.29
-3.38%
Despegar.com Corp
$2.29
-3.38%
Sonder Holdings Inc
$2.29
-3.38%
Flexshares Quality Dividend
$2.29
-3.38%
Star Group Lp
$2.29
-3.38%
Gamco Global Gold Natural Resources & Income Trust
$2.29
-3.38%
Radnet Inc
$2.29
-3.38%